CF PHARMTECH's self-developed inhaled powder aerosol candidate drug ICF001's IND application has been accepted by the NMPA.

CF PHARMTECH (02652) announced that the new drug clinical trial (IND) application for the inhaled powder candidate drug ICF001, developed independently by the company, has been accepted by the National Medical Products Administration of the People's Republic of China (NMPA). ICF001 is an innovative long-acting inhaled powder candidate drug developed independently based on prodrug technology platform, designed specifically for the treatment of pulmonary arterial hypertension and related severe lung diseases. In terms of molecular design and mechanism of action, the product transforms active molecules into prodrugs through specific chemical modifications, allowing for slow release of active ingredients dependent on the slow cleavage of endogenous enzymes in lung tissues after deposition in the lungs. Based on preclinical studies, this design is expected to deliver the drug to deep lung tissues while suppressing the peak blood concentration (Cmax) in the initial stage of administration and extending the local drug exposure time, exploring the potential to optimize the pharmacokinetic (PK) characteristics of the drug. The initial indications for ICF001 are pulmonary arterial hypertension (PAH; WHO class 1) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD; WHO class 3). PAH is a rare fatal disease and PH-ILD represents a larger patient population with relatively limited available treatments. Recent scientific research and clinical exploration of similar international projects has further suggested the dual potential of ICF001 to counteract pulmonary arterial hypertension and fibrosis through specific pathways. Therefore, based on this unique mechanism, ICF001 has future potential to expand into a larger patient population, including those with interstitial lung disease-related lung fibrosis, such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The announcement states that the acceptance of this application marks an important milestone for the group in entering clinical development in the high-barrier respiratory pipeline. The company believes that the focus of ICF001's development strategy is to explore potential improvements in tolerance and dosing efficiency, specifically focusing on the following directions: first, through synergistic optimization of molecular structure and formulation process, aiming to increase drug loading efficiency, reduce dosing burden, and enhance airway tolerance; secondly, aiming to optimize in vivo exposure characteristics, improve overall exposure performance while controlling peak blood concentrations to support more controllable dosing strategies. If the related mechanisms and clinical benefits are further confirmed in subsequent studies, it is expected to support more practical and controllable inhalation dosing strategies, improve long-term medication compliance, optimize therapeutic efficacy potential, and expand the clinical accessibility of the drug.